What are the indications, recommended dosing, and monitoring guidelines for Tenofovir alafenamide (TAF) in adult patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tenofovir Alafenamide (TAF): Clinical Indications, Dosing, and Monitoring

Tenofovir alafenamide (TAF) 25 mg once daily with food is indicated for chronic hepatitis B (CHB) in adults and children ≥6 years weighing ≥25 kg with compensated liver disease, offering superior renal and bone safety compared to tenofovir disoproxil fumarate (TDF). 1

Primary Indication

TAF is approved for treatment of chronic HBV infection in patients with compensated liver disease 2, 1. The 2025 EASL guidelines and FDA label establish TAF as a first-line nucleos(t)ide analogue (NA) with a high barrier to resistance, comparable efficacy to TDF, but with significantly improved safety profile 2, 1.

Recommended Dosing

Standard Dosing

  • Adults and children ≥6 years (≥25 kg): 25 mg orally once daily with food 1
  • Food increases absorption by 65%, making administration with meals essential 1

Renal Dose Adjustments

TAF requires minimal dose adjustment compared to TDF 3:

  • eGFR ≥15 mL/min: 25 mg once daily (no adjustment needed) 3, 1
  • eGFR <15 mL/min on hemodialysis: 25 mg once daily on hemodialysis days, administered after dialysis 3, 1
  • eGFR <15 mL/min without dialysis: Not recommended due to insufficient data 1

This represents a major advantage over TDF, which requires dose adjustments starting at eGFR <50 mL/min 3.

Hepatic Considerations

  • Compensated liver disease (Child-Pugh A): Standard dosing 1
  • Decompensated cirrhosis (Child-Pugh B or C): Not recommended due to lack of data 3, 1

Pre-Treatment Testing Requirements

Before initiating TAF, the following assessments are mandatory 4, 1:

  1. HIV testing: TAF alone should not be used in HIV-coinfected patients as it may lead to HIV resistance 4, 1
  2. Renal function: Serum creatinine, estimated creatinine clearance 4, 1
  3. Urinalysis: Urine glucose and urine protein 4, 1
  4. Serum phosphorus: Particularly in patients with chronic kidney disease 4, 1
  5. HBV DNA and ALT levels 2
  6. HBeAg status 2

Monitoring During Treatment

Virological and Biochemical Monitoring

Standard monitoring schedule 2, 4:

  • First year: HBV DNA and ALT every 3-4 months
  • After first year: HBV DNA and ALT every 6-12 months if virologically suppressed
  • HBsAg quantification: Annually to monitor for HBsAg loss 2
  • HBeAg status: Annually in HBeAg-positive patients to document seroconversion 2

The 2025 EASL guidelines note that with consistent adherence to TAF (along with entecavir and TDF), monitoring can be extended to 6-12 months due to low resistance risk 2. No resistance to TAF has been documented through 8 years of treatment 5.

Renal Safety Monitoring

TAF demonstrates superior renal safety compared to TDF, but monitoring remains important 2, 4:

Baseline and periodic assessment:

  • Serum creatinine and eGFR
  • Serum phosphorus (especially if chronic kidney disease present)
  • Urine protein and glucose 4, 1

Monitoring frequency:

  • Every 3 months during first year
  • Every 6 months thereafter if stable 6
  • More frequently if eGFR <60 mL/min or serum phosphorus <2 mg/dL 6

Key advantage: The 2025 EASL guidelines report that after 96 weeks, patients on TAF experienced significantly less decline in eGFR and bone mineral density (BMD) compared to TDF 2. Switching from TDF to TAF led to improvement in BMD in some cohorts 2.

Bone Safety Monitoring

While TAF has superior bone safety compared to TDF, monitoring is recommended in high-risk patients 2, 3:

High-risk populations requiring bone monitoring:

  • Postmenopausal women
  • Patients >60 years
  • Pre-existing osteopenia or osteoporosis
  • Chronic steroid use
  • Other medications affecting bone density 3

The 2022 KASL guidelines note that among patients with risk factors for decreased bone density (female, age >50 years, Asian, baseline eGFR <90 mL/min), TAF showed significantly less BMD decline (-1.23%) compared to TDF (-3.29%) 3.

Patient Selection: When to Prefer TAF Over Other NAs

TAF is Strongly Preferred in:

  1. Renal risk factors 4, 3:

    • Baseline eGFR <60 mL/min
    • Proteinuria or albuminuria (urine albumin:creatinine ratio >30 mg/g)
    • Hypophosphatemia (<2.5 mg/dL)
    • Uncontrolled diabetes or hypertension
    • Concomitant nephrotoxic medications

  2. Bone disease risk 3:

    • Osteopenia or osteoporosis
    • Chronic steroid therapy
    • Postmenopausal women
    • Age >60 years

  3. Patients currently on TDF with complications 4, 7:

    • Declining eGFR
    • Decreasing BMD
    • Fanconi syndrome
    • Hypophosphatemia

The 2018 AASLD guidance explicitly states: "In cases of suspected TDF-associated renal dysfunction and/or bone disease, TDF should be discontinued and substituted with TAF or entecavir" 4.

Switching from TDF to TAF

Indications for switching 2, 7, 8:

  • Development of renal dysfunction (eGFR decline)
  • Decreased bone mineral density
  • Presence of risk factors for renal or bone complications
  • Patient preference for improved safety profile

Expected improvements after switch 2, 7:

  • Improvement in eGFR (median recovery from -7.8 mL/min on TDF to near baseline after TAF switch) 7
  • Improvement in BMD (T-score changes from -0.09 on TDF to -0.0 after besifovir switch; similar improvements expected with TAF) 7
  • Stabilization of serum phosphorus levels

Common Pitfalls and Caveats

  1. HIV coinfection: Never use TAF monotherapy in HIV-coinfected patients—it can select for HIV resistance 4, 1. Always test for HIV before initiating TAF.

  2. Food requirement: TAF must be taken with food for optimal absorption (65% increase in AUC) 1. Fasting administration significantly reduces drug levels.

  3. Decompensated cirrhosis: TAF is not recommended in Child-Pugh B or C cirrhosis due to lack of safety data 3, 1.

  4. Treatment discontinuation: The FDA boxed warning emphasizes that discontinuation of anti-HBV therapy may result in severe acute exacerbations of hepatitis B 1. Hepatic function must be monitored closely for several months after stopping TAF, and resumption of therapy may be warranted 1.

  5. Pregnancy data: While TAF is used in HIV-infected pregnant women, data in HBV monoinfection during pregnancy are limited 9. The 2024 IAS-USA guidelines recommend dolutegravir with TAF/FTC as the preferred regimen in HIV-infected pregnant women 9.

  6. Drug interactions: TAF is a substrate of P-glycoprotein (P-gp) and BCRP 1. Drugs that strongly affect P-gp activity (e.g., rifampin) may alter TAF absorption. The 2024 IAS-USA guidelines note pharmacokinetic interactions between rifampin and TAF, though intracellular tenofovir-diphosphate concentrations remain adequate 9, 10.

Efficacy Data

At 96 weeks, TAF demonstrates 2, 6, 5:

  • HBeAg-positive patients: 75% virologic response (HBV DNA <29 IU/mL), 22% HBeAg loss, 18% anti-HBe seroconversion
  • HBeAg-negative patients: 90-94% virologic response
  • ALT normalization: Higher rates with TAF than TDF by AASLD criteria (75% vs 68% at week 96) 6
  • 8-year data: 95-97% virologic suppression with no resistance development 5

TAF is a highly effective, well-tolerated first-line agent for CHB with superior renal and bone safety compared to TDF, making it the preferred choice in patients with or at risk for renal or bone complications.

References

10
Research

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026

Related Questions

What is the appropriate tenofovir dosing regimen for chronic hepatitis B infection in adults and children, and how should the dose be adjusted in patients with renal impairment?
What is the newest approved oral antiviral treatment for chronic hepatitis B, including its dosing, indications, and monitoring?
Which tenofovir formulation is preferred for a patient with chronic obstructive pulmonary disease (COPD) receiving hepatitis B antiviral therapy and a history of pancreatitis?
What are the optimal antibiotics for an adult with chronic obstructive pulmonary disease (COPD) on tenofovir alafenamide for chronic hepatitis B and a history of pancreatitis?
At what level of alanine transaminase (ALT) or aspartate transaminase (AST) elevation should Descovy (emtricitabine and tenofovir alafenamide) be withheld?
When should recombinant human growth hormone therapy be discontinued after a child reaches the target height?
What medication regimen is recommended for a patient with anxiety experiencing feeling overwhelmed and loss of concentration?
In a 17-year-old with a spot urine protein of 12 mg and urine creatinine of 44.7 mg, what is the significance of the protein/creatinine ratio and what management steps are recommended?
What are the dosing recommendations and monitoring guidelines for low‑molecular‑weight heparin (LMWH) in adults with chronic kidney disease based on their creatinine clearance?
How long after an intracranial aneurysm coil embolization can therapeutic heparin be restarted?
What direct oral anticoagulant (DOAC) options and dosing adjustments are recommended for patients with chronic kidney disease (CKD) based on their estimated glomerular filtration rate (eGFR)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.